It's Friday. Today, we'll highlight some of the medical journal research we added to the LATESTBreastCancer.com database this week. Topics include prevention, radiation, metastatic treatment and music therapy.
For those concerned with breast cancer prevention, a study in the Journal of Clinical Oncology weighed the risks and benefits of tamoxifen and raloxifene (brand name Evista) for women over 50. The American researchers created an index to "complement clinical evaluation" of whether to start chemoprevention and the risks and benefits of tamoxifen and raloxifene.
There's been some concern about axillary failure (recurrence) after MammoSite accelerated partial breast irradiation, which does not treat the axillary region. A study published in the Annals of Surgical Oncology concluded that the rate of axillary failure after "MammoSite APBI is low and appears to be similar to that achieved with whole-breast irradiation."
For HER2 positive metastatic patients, a study in the Annals of Oncology found that prior exposure to trastuzumab-DMI "does not exhaust the potential benefit of ongoing anti-HER2 therapy with trastuzumab and/or lapatinib-based regimens."
Finally, a study in Breast Cancer Research and Treatment examined the effects of music therapy on post-matectomy pain. The Chinese researchers found "some evidence" that music therapy had both short and long-term positive effects on alleviating pain.
On Sunday, we'll highlight the weekend breast cancer news. Please stay tuned.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment